Pfizer announced a multimillion-dollar investment to double its health impact on patients in Mexico as the company marks its 75th anniversary [1].

This expansion aims to reinforce the national health system by increasing local production and improving patient access to medicine. By leveraging its existing infrastructure, the company intends to scale its operations to meet growing domestic demand.

A central pillar of this strategy is the manufacturing plant located in Toluca, State of Mexico [2]. The facility serves as a critical hub for both domestic supply and international trade. According to company data, the Toluca plant produced 194 million units in 2025 [2].

Distribution from the Toluca facility is split between local and global markets. Approximately 70% of the production is destined for the Mexican market [2]. The remaining 30% of the units are used for export [2].

Governor Delfina Gómez Álvarez recognized the company's long-term presence during the commemoration of the 75-year milestone [2]. The investment is designed to support the Mexican government's efforts to stabilize and improve the public health infrastructure through increased availability of pharmaceutical products [3].

Pfizer has operated in Mexico for 75 years [1]. The company said the new investment will allow it to double its impact on patients across the country [3].

“Pfizer announced a multimillion-dollar investment to double its health impact on patients in Mexico”

Pfizer's decision to scale production in Toluca indicates a strategic shift toward localization in the Latin American market. By dedicating the vast majority of its local output to domestic consumption, the company reduces reliance on imports and mitigates supply chain risks, while aligning itself with the Mexican government's goals for health system sustainability.